{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:04:19Z","timestamp":1785423859444,"version":"3.56.0"},"reference-count":30,"publisher":"Vilnius University Press","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>Background: This study aimed to evaluate the prevalence and severity of gastrointestinal (GI) symptoms in patients with systemic sclerosis (SSc), their impact on social functioning and emotional well-being, and to compare findings between patients with limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc), as well as between patients positive for anticentromere (ACA) or anti-topoisomerase I (ATA) antibodies.Materials and methods: Forty-two consecutive patients with SSc were included: 31 with lcSSc and 11 with dcSSc. ACA antibodies were detected in 26 patients, and ATA antibodies in 16 patients. The UCLA SCTC GIT 2.0 self-assessment questionnaire was used to assess the severity of GI symptoms across seven subscales: reflux, distention\/bloating, diarrhea, fecal soilage, constipation, social functioning, and emotional well-being.Results: Symptoms of reflux (lcSSc\/dcSSc = 64.5%\/81.8%), distention\/bloating (lcSSc\/dcSSc = 61.3%\/81.8%), constipation (lcSSc\/dcSSc = 45.2%\/45.5%), and fecal soilage (lcSSc\/dcSSc = 6.4%\/18.2%) were similarly frequent in lcSSc and dcSSc. Diarrhea was more common in dcSSc (45.5% vs. 16.1%, p = 0.04), with a higher median index value (0.25 vs. 0.00, p = 0.02), thus indicating more severe symptoms. No differences were observed in the prevalence or severity of GI symptoms between ACA- and ATA-positive patients. Median index values for social functioning and emotional well-being did not differ by the disease subtype or antibody status.Conclusions: Diarrhea was more prevalent and more severe in patients with dcSSc, while other gastrointestinal manifestations showed no major differences between subtypes. Symptom prevalence and severity did not differ according to the antibody status, and their impact on social and emotional functioning was similar across the groups.<\/jats:p>","DOI":"10.15388\/amed.2026.33.1.13","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:35:03Z","timestamp":1784698503000},"page":"161-168","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal Symptoms in Systemic Sclerosis: Prevalence and Severity across Disease Subtypes and Autoantibody Profiles"],"prefix":"10.15388","volume":"33","author":[{"given":"Marina","family":"Vujovi\u0107 \u0160estakov","sequence":"first","affiliation":[{"name":"Institute of Rheumatology, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sretko","family":"Lukovic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Zlatanovic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Serbia"},{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Ostojic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Serbia"},{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Belgrade"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6097","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref0","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37(9):1265-1282. doi:10.1002\/art.1780370902","DOI":"10.1002\/art.1780370902"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, et al. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS One. 2016;11(10):e0163894. doi:10.1371\/journal.pone.0163894","DOI":"10.1371\/journal.pone.0163894"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel A V, et al. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford). 2010;49(9):1770-1775. doi:10.1093\/rheumatology\/keq147","DOI":"10.1093\/rheumatology\/keq147"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Sallam H, McNearney TA, Chen JDZ. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691-712. doi:10.1111\/j.1365-2036.2006.02804.x","DOI":"10.1111\/j.1365-2036.2006.02804.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Robinson D, Eisenberg D, Nietert PJ, Doyle M, Bala M et al. Systemic sclerosis prevalence and comorbidities in the United States, 2001-2002. Curr Med Res Opin. 2008;24(4):1157-1166. doi:10.1185\/030079908x280617","DOI":"10.1185\/030079908X280617"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Savarino E, Bredenoord AJ, Fox M, Pandolfino JE, Roman S, et al. Expert consensus document: advances in the physiological assessment and diagnosis of gastroesophageal reflux disease. Nat Rev Gastroenterol Hepatol. 2017;14(11):665-676. doi:10.1038\/nrgastro.2017.130","DOI":"10.1038\/nrgastro.2017.130"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kedia S, Chhaparia A, Garg P. Gastro-intestinal Involvement in Systemic Sclerosis. Indian J Rheumatol. 2017;12(2S):156-166. doi:10.4103\/0973-3698.219088","DOI":"10.4103\/0973-3698.219088"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Marie I, Ducrott\u00e9 P, Denis P, Menard JF, Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009;48(10):1314-1319. doi:10.1093\/rheumatology\/kep226","DOI":"10.1093\/rheumatology\/kep226"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Martin M, Meaux-Ruault N, Magy-Bertrand N, Beraud G, Parratte B et al. Anal incontinence and vesico-sphincter events in systemic sclerosis: An epidemiologic bicentric cohort study. Semin Arthritis Rheum. 2016;46(1):124-132. doi:10.1016\/j.semarthrit.2016.03.013","DOI":"10.1016\/j.semarthrit.2016.03.013"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi:10.1136\/annrheumdis-2013-204424","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Khanna D, Hays RD, Maranian P, Seibold JR, Impens A et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61(9):1257-1263. doi:10.1002\/art.24730","DOI":"10.1002\/art.24730"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Zekovic A, Damjanov N. Validation of the Serbian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. Rheumatology Int. 2017;37(5):735-741. doi:10.1007\/s00296-017-3680-y","DOI":"10.1007\/s00296-017-3680-y"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Khanna D, Furst DE, Maranian P, Seibold JR, Impens A, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol. 2011;38(9):1920-1924. doi:10.3899\/jrheum.110225","DOI":"10.3899\/jrheum.110225"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ostoji\u0107 P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol. 2006;25(4):453-457. doi:10.1007\/s10067-005-0041-0","DOI":"10.1007\/s10067-005-0041-0"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Roth E, Bruni C, Petelytska L, Becker MO, Dobrota R, et al. Gastroesophageal reflux disease is associated with more severe interstitial lung disease in systemic sclerosis: data from the EUSTAR cohort. Rheumatology (Oxford). 2025;64(SI):SI63-SI72. doi:10.1093\/rheumatology\/keaf016","DOI":"10.1093\/rheumatology\/keaf016"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"den Braber-Ymker M, Vonk MC, Gr\u00fcnberg K, Lammens M, Nagtegaal ID. Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events. Clin Rheumatol. 2021;40(3):981-990. doi:10.1007\/s10067-020-05325-8","DOI":"10.1007\/s10067-020-05325-8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Adler B, Hummers LK, Pasricha PJ, McMahan ZH. Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy. Rheumatology (Oxford). 2022;61(11):4503-4508. doi:10.1093\/rheumatology\/keac074","DOI":"10.1093\/rheumatology\/keac074"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Meier FMP, Frommer KW, Dinser R, Walker UA, Czirjak L, et al. Update on the profile of the EUSTAR cohort. Ann Rheum Dis. 2012;71(8):1355-1360. doi:10.1136\/annrheumdis-2011-200742","DOI":"10.1136\/annrheumdis-2011-200742"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Omair MA, Lee P. Effect of gastrointestinal manifestations on quality of life in patients with systemic sclerosis. J Rheumatol. 2012;39(5):992-996. doi:10.3899\/jrheum.110826","DOI":"10.3899\/jrheum.110826"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Shah A, Pakeerathan V, Jones MP, Kashyap PC, Virgo K, et al. Small intestinal bacterial overgrowth complicating gastrointestinal manifestations of systemic sclerosis: a systematic review and meta-analysis. J Neurogastroenterol Motil. 2023;29(2):132-144. doi:10.5056\/jnm22168","DOI":"10.5056\/jnm22168"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol. 2018;24(6):328-337. doi:10.1097\/RHU.0000000000000626","DOI":"10.1097\/RHU.0000000000000626"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Sawadpanich K, Soison P, Chunlertrith K, Mairiang P, Sukeepaisarnjaroen W, et al. Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. Int J Rheum Dis. 2019;22(4):695-699. doi:10.1111\/1756-185X.13495","DOI":"10.1111\/1756-185X.13495"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO). Curr Gastroenterol Rep. 2019;21(1):3. doi:10.1007\/s11894-019-0671-z","DOI":"10.1007\/s11894-019-0671-z"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Cano-Garc\u00eda L, Redondo-Rodr\u00edguez R, Mena-V\u00e1zquez N, Manrique-Arija S, Garc\u00eda-Studer A, et al. Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study. BMJ Open. 2024;14(4):e083419. doi:10.1136\/bmjopen-2023-083419","DOI":"10.1136\/bmjopen-2023-083419"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Fynne L, Wors\u00f8e J, Laurberg S, Krogh K. Faecal incontinence in patients with systemic sclerosis: is an impaired internal anal sphincter the only cause? Scand J Rheumatol. 2011;40(6):462-466. doi:10.3109\/03009742.2011.579575","DOI":"10.3109\/03009742.2011.579575"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Garros A, Marjoux S, Khouatra C, Coppere B, Grange C, et al. Prevalence of fecal incontinence in a cohort of systemic sclerosis patients within a regional referral network. United European Gastroenterol J. 2017;5(7):1046-1050. doi:10.1177\/2050640616688129","DOI":"10.1177\/2050640616688129"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Richard N, Hudson M, Gyger G, Baron M, Sutton E, et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology (Oxford). 2017;56(4):581-588. doi:10.1093\/rheumatology\/kew441","DOI":"10.1093\/rheumatology\/kew441"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Vettori S, Tolone S, Capocotta D, Chieffo R, Giacco V, et al. Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin Rheumatol. 2018;37(5):1239-1247. doi:10.1007\/s10067-018-4026-1","DOI":"10.1007\/s10067-018-4026-1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, et al. Esophageal dysmotility in scleroderma: a prospective study of 183 cases. Gastroenterol Clin Biol. 2009;33(6-7):466-469. doi:10.1016\/j.gcb.2009.01.014","DOI":"10.1016\/j.gcb.2009.01.014"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/44926\/42907","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/44926\/42932","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/download\/44926\/42907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:28:28Z","timestamp":1784716108000},"score":1,"resource":{"primary":{"URL":"https:\/\/zurnalai.vu.lt\/\/AML\/article\/view\/44926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2026.33.1.13","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"value":"2029-4174","type":"electronic"},{"value":"1392-0138","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}